(Q37766266)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

0 references

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Robert A Mitchell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Nathan Herrmann

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

16 June 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

CNS Neuroscience & Therapeutics

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

411-427

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

Changing the trajectory of cognitive decline?

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Worldwide prevalence and incidence of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The clinical course of advanced dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Reliability and validity of the apathy evaluation scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The spectrum of behavioral changes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Executive dysfunction and apathy predict functional impairment in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Predictors of institutionalisation in people with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Memantine for behavioral disturbances in frontotemporal dementia: a case series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Addictive Drugs and Brain Stimulation Reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The role of dopamine in reward and pleasure behaviour--review of data from preclinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A SPECT study of apathy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The neurobiology of dopamine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Dendritic release of dopamine in the substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Frontal-subcortical circuits and neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Ageing and the nigrostriatal dopaminergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Dopamine neurons and their role in reward mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Changes of Biogenic Amines and Their Metabolites in Postmortem Brains from Patients with Alzheimer-Type Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a postmortem study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and down's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Monoamine metabolism in senile dementia of Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Striatal dopamine receptors in Alzheimer-type dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

D1-dopamine receptor abnormality in frontal cortex points to a functional alteration of cortical cell membranes in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Immunohistochemical localization of dopamine receptor subtypes (D1R-D5R) in Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Dopamine D2 receptors are organized in bands in normal human temporal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Linking the family of D2 receptors to neuronal circuits in human brain: insights into schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Investigation of the role of the dopamine transporter in susceptibility to behavioural and psychological symptoms of patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Reduced striatal dopamine receptors in Alzheimer's disease: single photon emission tomography study with the D2 tracer [123I]-IBZM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Decreased striatal D2 receptor density associated with severe behavioral abnormality in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Assessment of dopamine metabolism in brain of patients with dementia by means of 18F-fluorodopa and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Loss of dopamine uptake sites labeled with [3H]GBR-12935 in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Striatal uptake of the dopamine reuptake ligand [11C]beta-CFT is reduced in Alzheimer's disease assessed by positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The debate over dopamine's role in reward: the case for incentive salience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Cellular and molecular mechanisms of drug dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The behavioral neurochemistry of motivation: methodological and conceptual issues in studies of the dynamic activity of nucleus accumbens dopamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A neural substrate of prediction and reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Neurobiology of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Behavioral and psychological symptoms in Alzheimer's disease. Relation between apathy and regional cerebral perfusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Cerebral blood flow correlates of apathy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Lack of initiative and interest in Alzheimer's disease: a single photon emission computed tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Brain perfusion correlates of the apathy inventory dimensions of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Brain perfusion in Alzheimer's disease with and without apathy: a SPECT study with statistical parametric mapping analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Apathy and loss of insight in Alzheimer's disease: a SPECT imaging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Apathy in Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

21 January 2018

Apathy is not depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Differential diagnosis and classification of apathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The sources of convergence between measures of apathy and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Syndromic validity of apathy in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Contributions of anterior cingulate cortex to behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Intensely pleasurable responses to music correlate with activity in brain regions implicated in reward and emotion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Reward signaling by dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Relative reward preference in primate orbitofrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Apathy is a prominent neuropsychiatric feature of radiological white-matter changes in patients with dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Positron emission tomography metabolic correlates of apathy in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Neuropathology of white matter lesions in vascular cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Morphologic diagnosis of "vascular dementia" - a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Extrapyramidal signs in patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Extrapyramidalism in Alzheimer's disease: prevalence, psychiatric, and neuropsychological correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Extrapyramidal signs in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Predictors of behavioral disturbance in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Apathy predicts more severe parkinsonism in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Loss of dopamine D2 receptors in Alzheimer's disease with parkinsonism but not Parkinson's or Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Cholinergic drugs for Alzheimer's disease enhance in vitro dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Behavioral effects of current Alzheimer's disease treatments: a descriptive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Amantadine for executive dysfunction syndrome in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Levodopa and bromocriptine in hypoxic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Apathy associated with Alzheimer disease: use of dextroamphetamine challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Effects of methylphenidate on cognition and apathy in normal pressure hydrocephalus: a case study and review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Reversal of Anorexia by Methylphenidate in Apathetic, Severely Demented Nursing Home Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Methylphenidate may treat apathy independent of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Methylphenidate for apathy and functional status in dementia of the Alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A possible case of peduncular hallucinosis in a patient with Parkinson's disease successfully treated with quetiapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Methylphenidate: its pharmacology and uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Autoradiographic localization of [3H]methylphenidate binding sites in rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Treatment of attention-deficit-hyperactivity disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Differences in the effects of amphetamine and methylphenidate on brain dopamine turnover and serum prolactin concentration in reserpine-treated rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Acute administration of d-amphetamine decreases impulsivity in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Amphetamine: effects on catecholamine systems and behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

An evaluation of the abuse potential of modafinil using methylphenidate as a reference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Acute behavioral and physiological effects of modafinil in drug abusers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Effects of modafinil on cognitive and meta-cognitive performance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Cognitive enhancing effects of modafinil in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Clinical pharmacokinetics of amantadine hydrochloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Bromocriptine and psychosis: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Methylphenidate treatment of negative symptoms in patients with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

21 January 2018

2 references

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

21 January 2018

12 December 2020

Stimulant treatment of frontotemporal dementia in 8 patients

2 references

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

21 January 2018

12 December 2020

Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00161.X

Apathy: Concept, Syndrome, Neural Mechanisms, and Treatment.

21 January 2018

1 reference

12 December 2020

Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors.

1 reference

12 December 2020

A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study.

1 reference

12 December 2020

Dual effects of D-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors

1 reference

12 December 2020

SPECT tracer [(123)I]IBZM has similar affinity to dopamine D2 and D3 receptors

1 reference

12 December 2020

Hypothalamic arousal regions are activated during modafinil-induced wakefulness.

1 reference

12 December 2020

Psychiatric symptoms associated with cortical-subcortical dysfunction in Alzheimer's disease.

1 reference

12 December 2020

Dopaminergic role in stimulant-induced wakefulness.

1 reference

12 December 2020

Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease

1 reference

12 December 2020

Methylphenidate treats apathy in Parkinson's disease

1 reference

12 December 2020

THE ADDICTION RESEARCH CENTER INVENTORY: STANDARDIZATION OF SCALES WHICH EVALUATE SUBJECTIVE EFFECTS OF MORPHINE, AMPHETAMINE, PENTOBARBITAL, ALCOHOL, LSD-25, PYRAHEXYL AND CHLORPROMAZINE

1 reference

12 December 2020

Application of MRI-based partial-volume correction to the analysis of PET images of mu-opioid receptors using statistical parametric mapping.

1 reference

12 December 2020

The role of norepinephrine in the behavioral and psychological symptoms of dementia

1 reference

12 December 2020

Neuropsychiatric symptoms, functional impairment and executive ability in Thai patients with Alzheimer's disease.

1 reference

12 December 2020

Modafinil: the unique properties of a new stimulant.

1 reference

12 December 2020

The contribution of neuropsychiatric symptoms to the cost of dementia care

1 reference

12 December 2020

Modafinil therapy for apathy in an elderly patient

1 reference

12 December 2020

Treatment of apathy with methylphenidate.

1 reference

12 December 2020

Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial.

1 reference

12 December 2020

Imaging of mild cognitive impairment and early dementia

1 reference

12 December 2020

The pathology of "vascular dementia": a critical update

1 reference

12 December 2020

Apathy due to cerebrovascular accidents successfully treated with methylphenidate: a case series

1 reference

12 December 2020

Neuroimaging correlates of apathy and depression in Alzheimer's disease.

1 reference

12 December 2020

Use of psychostimulants for the elderly

1 reference

12 December 2020

Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum

1 reference

12 December 2020

A psychomotor stimulant theory of addiction.

1 reference

12 December 2020

Modafinil: a double-blind multicentric study.

1 reference

12 December 2020

Apathy: a treatable syndrome

1 reference

12 December 2020

SPECT imaging of striatal dopamine release after amphetamine challenge.

1 reference

12 December 2020

Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine

1 reference

12 December 2020

Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter

1 reference

12 December 2020

N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury

1 reference

12 December 2020

Modafinil binds to the dopamine uptake carrier site with low affinity.

1 reference

12 December 2020

Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients

1 reference

12 December 2020

Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants.

1 reference

12 December 2020

Predicting time to nursing home care and death in individuals with Alzheimer disease.

1 reference

12 December 2020

Hedonic valence, dopamine and motivation.

1 reference

12 December 2020

Behaviour disturbance and other predictors of carer burden in Alzheimer's disease

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy

1 reference

12 December 2020

Predictive reward signal of dopamine neurons

1 reference

12 December 2020

10.1111/J.1755-5949.2010.00161.X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20560994%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference